

# **Pulmonary Arterial Hypertension Drugs Market Size, Trends, Analysis, and Outlook By Mechanism of Action (Prostacyclin Analogs, Endothelin Receptor Antagonists (ERAs), Phosphodiesterase (PDE) Inhibitors, Soluble Guanylate Cyclase Stimulators (SGCSs)), By Route of Administration ( Oral, Injectable, Inhalation), by Region, Country, Segment, and Companies, 2024-2030**

<https://marketpublishers.com/r/P60D2CB290E4EN.html>

Date: March 2024

Pages: 190

Price: US\$ 3,980.00 (Single User License)

ID: P60D2CB290E4EN

## **Abstracts**

The global Pulmonary Arterial Hypertension Drugs market size is poised to register 5.99% growth (CAGR) from 2024 to 2030, presenting significant growth prospects for companies operating in the industry. The industry study analyzes the global Pulmonary Arterial Hypertension Drugs market By Mechanism of Action (Prostacyclin Analogs, Endothelin Receptor Antagonists (ERAs), Phosphodiesterase (PDE) Inhibitors, Soluble Guanylate Cyclase Stimulators (SGCSs)), By Route of Administration ( Oral, Injectable, Inhalation).

Pulmonary arterial hypertension (PAH) is a progressive and life-threatening condition characterized by elevated blood pressure in the pulmonary arteries, leading to right heart failure and premature death. Key trends in PAH drug development include the identification of novel targets and pathways involved in pulmonary vascular remodeling, endothelial dysfunction, and vasoconstriction, leading to the development of targeted therapies with vasodilatory, antiproliferative, and antifibrotic effects. Additionally, there's growing interest in combination therapies incorporating multiple classes of PAH drugs, such as endothelin receptor antagonists, phosphodiesterase type 5 (PDE5) inhibitors, and soluble guanylate cyclase (sGC) stimulators, for their synergistic effects and

enhanced efficacy in improving exercise capacity, hemodynamics, and survival in PAH patients. Moreover, advancements in drug delivery systems, including oral tablets, inhalation therapies, and subcutaneous injections, are enhancing treatment adherence, convenience, and patient compliance, offering personalized treatment options for patients with PAH and improving their quality of life..

## Pulmonary Arterial Hypertension Drugs Market Drivers, Trends, Opportunities, and Growth Opportunities

This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The Pulmonary Arterial Hypertension Drugs market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of Pulmonary Arterial Hypertension Drugs survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the Pulmonary Arterial Hypertension Drugs industry.

## Key market trends defining the global Pulmonary Arterial Hypertension Drugs demand in 2024 and Beyond

The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.

## Pulmonary Arterial Hypertension Drugs Market Segmentation- Industry Share, Market Size, and Outlook to 2030

The Pulmonary Arterial Hypertension Drugs industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is supporting companies to increase their investment levels across niche segments. Accordingly, leading companies plan to generate a large share of their future revenue growth from expansion into these niche segments. The report presents the market size outlook across segments to support Pulmonary Arterial Hypertension Drugs companies scaling up production in these sub-segments with a focus on expanding into emerging countries.

## Key strategies adopted by companies within the Pulmonary Arterial Hypertension Drugs industry

Leading Pulmonary Arterial Hypertension Drugs companies are boosting investments to capitalize on untapped potential and future possibilities across niche market segments and surging demand conditions in key regions. Further, companies are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The report provides key strategies opted for by the top 10 Pulmonary Arterial Hypertension Drugs companies.

### Pulmonary Arterial Hypertension Drugs Market Study- Strategic Analysis Review

The Pulmonary Arterial Hypertension Drugs market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-

**Industry Dynamics:** Porter's Five Forces analysis to understand bargaining power, competitive rivalry, and threats that impact long-term strategy formulation.

**Strategic Insights:** Provides valuable perspectives on key players and their approaches based on comprehensive strategy analysis.

**Internal Strengths and Weaknesses:** Develop targeted strategies to leverage strengths, address weaknesses, and capitalize on market opportunities.

**Future Possibilities:** Prepare for diverse outcomes with in-depth scenario analysis. Explore potential market disruptions, technology advancements, and economic changes.

### Pulmonary Arterial Hypertension Drugs Market Size Outlook- Historic and Forecast Revenue in Three Cases

The Pulmonary Arterial Hypertension Drugs industry report provides a detailed analysis and outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to 2030 in three case scenarios- low case, reference case, and high case scenarios.

### Pulmonary Arterial Hypertension Drugs Country Analysis and Revenue Outlook to 2030

The report analyses 22 countries worldwide including the key driving forces and market

size outlook from 2021 to 2030. In addition, region analysis across Asia Pacific, Europe, the Middle East, Africa, North America, and South America is included in the study. For each of the six regions, the market size outlook by segments is forecast for 2030.

### North America Pulmonary Arterial Hypertension Drugs Market Size Outlook- Companies plan for focused investments in a changing environment

The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong end-user industry demand. Leading companies focus on new product launches in the changing environment. The US economy is expected to grow in 2024 (around 2.2% growth in 2024), potentially driving demand for various Pulmonary Arterial Hypertension Drugs market segments. Similarly, Strong end-user demand is encouraging Canadian Pulmonary Arterial Hypertension Drugs companies to invest in niche segments. Further, as Mexico continues to strengthen its trade relations and invest in technological advancements, the Mexico Pulmonary Arterial Hypertension Drugs market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.

### Europe Pulmonary Arterial Hypertension Drugs Market Size Outlook-Companies investing in assessing consumers, categories, competitors, and capabilities

The German industry remains the major market for companies in the European Pulmonary Arterial Hypertension Drugs industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period, driving the overall market prospects. In addition, the proactive approach of businesses in identifying and leveraging new growth prospects positions the European Pulmonary Arterial Hypertension Drugs market for an upward trajectory, fostering both domestic and international interest. Leading brands operating in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen understanding of consumer preferences.

### Asia Pacific Pulmonary Arterial Hypertension Drugs Market Size Outlook- an attractive hub for opportunities for both local and global companies

The increasing prevalence of indications, robust healthcare expenditure, and increasing investments in healthcare infrastructure drive the demand for Pulmonary Arterial Hypertension Drugs in Asia Pacific. In particular, China, India, and South East Asian Pulmonary Arterial Hypertension Drugs markets present a compelling outlook for 2030,

acting as a magnet for both domestic and multinational manufacturers seeking growth opportunities. Similarly, with a burgeoning population and a rising middle class, India offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes in-depth interviews with industry experts and comprehensive data analysis to provide a comprehensive outlook of 6 major markets in the region.

### Latin America Pulmonary Arterial Hypertension Drugs Market Size Outlook- Continued urbanization and rising income levels

Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.

### Middle East and Africa Pulmonary Arterial Hypertension Drugs Market Size Outlook- continues its upward trajectory across segments

Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East Pulmonary Arterial Hypertension Drugs market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for Pulmonary Arterial Hypertension Drugs.

### Pulmonary Arterial Hypertension Drugs Market Company Profiles

The global Pulmonary Arterial Hypertension Drugs market is characterized by intense competitive conditions with leading companies opting for aggressive marketing to gain market shares. The report presents business descriptions, SWOT analysis, growth strategies, and financial profiles. Leading companies included in the study are Asklepiion Pharmaceuticals LLC, AstraZeneca Plc, Bayer AG, Daiichi Sankyo Co. Ltd, Dr Reddys Laboratories Ltd, Eiger BioPharmaceuticals Inc, Gilead Sciences Inc, GlaxoSmithKline Plc, Johnson and Johnson Services Inc, Lupin Ltd, Merck and Co. Inc, Novartis AG, Pfizer Inc, Teva Pharmaceutical Industries Ltd, United Therapeutics Corp.

### Recent Pulmonary Arterial Hypertension Drugs Market Developments

The global Pulmonary Arterial Hypertension Drugs market study presents recent market

news and developments including new product launches, mergers, acquisitions, expansions, product approvals, and other updates in the industry.

Pulmonary Arterial Hypertension Drugs Market Report Scope

Parameters: Revenue, Volume Price

Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2030 (Forecast Period)

Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local Currency)

Qualitative Analysis

Pricing Analysis

Value Chain Analysis

SWOT Profile

Market Dynamics- Trends, Drivers, Challenges

Porter's Five Forces Analysis

Macroeconomic Impact Analysis

Case Scenarios- Low, Base, High

Market Segmentation:

By Type

Stationary 3D and 4D Ultrasound Devices

Portable 3D and 4D Ultrasound Devices

By Display

Color Ultrasound

B/W Ultrasound

By Portability

Trolley or Cart-Based Ultrasound Systems

Compact/Handheld Ultrasound Systems

Point-of-Pare (PoC) Ultrasound Systems

By Application

Radiology or General Imaging

Obstetrics or Gynecology

Cardiology

Urology

Vascular

Orthopedic and Musculoskeletal

Pain Management

Others

By End-User

Hospitals

Surgical Centers and Diagnostic Centers

Maternity Centers

Ambulatory Care Centers

Research and Academia

Others

Geographical Segmentation:

North America (3 markets)

Europe (6 markets)

Asia Pacific (6 markets)

Latin America (3 markets)

Middle East Africa (5 markets)

Companies

Asklepion Pharmaceuticals LLC

AstraZeneca Plc

Bayer AG

Daiichi Sankyo Co. Ltd

Dr Reddys Laboratories Ltd

Eiger BioPharmaceuticals Inc

Gilead Sciences Inc

GlaxoSmithKline Plc

Johnson and Johnson Services Inc



Lupin Ltd

Merck and Co. Inc

Novartis AG

Pfizer Inc

Teva Pharmaceutical Industries Ltd

United Therapeutics Corp

Formats Available: Excel, PDF, and PPT

## Contents

### **1. EXECUTIVE SUMMARY**

- 1.1 Pulmonary Arterial Hypertension Drugs Market Overview and Key Findings, 2024
- 1.2 Pulmonary Arterial Hypertension Drugs Market Size and Growth Outlook, 2021-2030
- 1.3 Pulmonary Arterial Hypertension Drugs Market Growth Opportunities to 2030
- 1.4 Key Pulmonary Arterial Hypertension Drugs Market Trends and Challenges
  - 1.4.1 Pulmonary Arterial Hypertension Drugs Market Drivers and Trends
  - 1.4.2 Pulmonary Arterial Hypertension Drugs Market Challenges
- 1.5 Competitive Landscape and Key Players
- 1.6 Competitive Analysis- Growth Strategies Adopted by Leading Pulmonary Arterial Hypertension Drugs Companies

### **2. PULMONARY ARTERIAL HYPERTENSION DRUGS MARKET SIZE OUTLOOK TO 2030**

- 2.1 Pulmonary Arterial Hypertension Drugs Market Size Outlook, USD Million, 2021-2030
- 2.2 Pulmonary Arterial Hypertension Drugs Incremental Market Growth Outlook, %, 2021- 2030
- 2.3 Segment Snapshot, 2024

### **3. PULMONARY ARTERIAL HYPERTENSION DRUGS MARKET- STRATEGIC ANALYSIS REVIEW**

- 3.1 Porter's Five Forces Analysis
  - \* Threat of New Entrants
  - \* Threat of Substitutes
  - \* Intensity of Competitive Rivalry
  - \* Bargaining Power of Buyers
  - \* Bargaining Power of Suppliers
- 3.2 Value Chain Analysis
- 3.3 SWOT Analysis

### **4. PULMONARY ARTERIAL HYPERTENSION DRUGS MARKET SEGMENTATION ANALYSIS AND OUTLOOK**

#### 4.1 Market Segmentation and Scope

#### 4.2 Market Breakdown by Type, Application, and Other Segments, 2021-2030

##### By Type

Stationary 3D and 4D Ultrasound Devices

Portable 3D and 4D Ultrasound Devices

##### By Display

Color Ultrasound

B/W Ultrasound

##### By Portability

Trolley or Cart-Based Ultrasound Systems

Compact/Handheld Ultrasound Systems

Point-of-Pare (PoC) Ultrasound Systems

##### By Application

Radiology or General Imaging

Obstetrics or Gynecology

Cardiology

Urology

Vascular

Orthopedic and Musculoskeletal

Pain Management

Others

##### By End-User

Hospitals

Surgical Centers and Diagnostic Centers

Maternity Centers

Ambulatory Care Centers

Research and Academia

Others

#### 4.3 Growth Prospects and Niche Opportunities, 2023- 2030

#### 4.4 Regional comparison of Market Growth, CAGR, 2023-2030

### 5. REGION-WISE MARKET OUTLOOK TO 2030

#### 5.1 Key Findings for Asia Pacific Pulmonary Arterial Hypertension Drugs Market, 2025

#### 5.2 Asia Pacific Pulmonary Arterial Hypertension Drugs Market Size Outlook by Type, 2021- 2030

#### 5.3 Asia Pacific Pulmonary Arterial Hypertension Drugs Market Size Outlook by Application, 2021- 2030

#### 5.4 Key Findings for Europe Pulmonary Arterial Hypertension Drugs Market, 2025

5.5 Europe Pulmonary Arterial Hypertension Drugs Market Size Outlook by Type, 2021-2030

5.6 Europe Pulmonary Arterial Hypertension Drugs Market Size Outlook by Application, 2021- 2030

5.7 Key Findings for North America Pulmonary Arterial Hypertension Drugs Market, 2025

5.8 North America Pulmonary Arterial Hypertension Drugs Market Size Outlook by Type, 2021- 2030

5.9 North America Pulmonary Arterial Hypertension Drugs Market Size Outlook by Application, 2021- 2030

5.10 Key Findings for South America Pulmonary Arterial Hypertension Drugs Market, 2025

5.11 South America Pacific Pulmonary Arterial Hypertension Drugs Market Size Outlook by Type, 2021- 2030

5.12 South America Pulmonary Arterial Hypertension Drugs Market Size Outlook by Application, 2021- 2030

5.13 Key Findings for Middle East and Africa Pulmonary Arterial Hypertension Drugs Market, 2025

5.14 Middle East Africa Pulmonary Arterial Hypertension Drugs Market Size Outlook by Type, 2021- 2030

5.15 Middle East Africa Pulmonary Arterial Hypertension Drugs Market Size Outlook by Application, 2021- 2030

## **6. COUNTRY-WISE MARKET SIZE OUTLOOK TO 2030**

6.1 US Pulmonary Arterial Hypertension Drugs Market Size Outlook and Revenue Growth Forecasts

6.2 US Pulmonary Arterial Hypertension Drugs Industry Drivers and Opportunities

6.3 Canada Market Size Outlook and Revenue Growth Forecasts

6.4 Canada Pulmonary Arterial Hypertension Drugs Industry Drivers and Opportunities

6.6 Mexico Market Size Outlook and Revenue Growth Forecasts

6.6 Mexico Pulmonary Arterial Hypertension Drugs Industry Drivers and Opportunities

6.7 Germany Market Size Outlook and Revenue Growth Forecasts

6.8 Germany Pulmonary Arterial Hypertension Drugs Industry Drivers and Opportunities

6.9 France Market Size Outlook and Revenue Growth Forecasts

6.10 France Pulmonary Arterial Hypertension Drugs Industry Drivers and Opportunities

6.11 UK Market Size Outlook and Revenue Growth Forecasts

6.12 UK Pulmonary Arterial Hypertension Drugs Industry Drivers and Opportunities

6.13 Spain Market Size Outlook and Revenue Growth Forecasts

- 6.14 Spain Pulmonary Arterial Hypertension Drugs Industry Drivers and Opportunities
- 6.16 Italy Market Size Outlook and Revenue Growth Forecasts
- 6.16 Italy Pulmonary Arterial Hypertension Drugs Industry Drivers and Opportunities
- 6.17 Rest of Europe Market Size Outlook and Revenue Growth Forecasts
- 6.18 Rest of Europe Pulmonary Arterial Hypertension Drugs Industry Drivers and Opportunities
- 6.19 China Market Size Outlook and Revenue Growth Forecasts
- 6.20 China Pulmonary Arterial Hypertension Drugs Industry Drivers and Opportunities
- 6.21 India Market Size Outlook and Revenue Growth Forecasts
- 6.22 India Pulmonary Arterial Hypertension Drugs Industry Drivers and Opportunities
- 6.23 Japan Market Size Outlook and Revenue Growth Forecasts
- 6.24 Japan Pulmonary Arterial Hypertension Drugs Industry Drivers and Opportunities
- 6.26 South Korea Market Size Outlook and Revenue Growth Forecasts
- 6.26 South Korea Pulmonary Arterial Hypertension Drugs Industry Drivers and Opportunities
- 6.27 Australia Market Size Outlook and Revenue Growth Forecasts
- 6.28 Australia Pulmonary Arterial Hypertension Drugs Industry Drivers and Opportunities
- 6.29 South East Asia Market Size Outlook and Revenue Growth Forecasts
- 6.30 South East Asia Pulmonary Arterial Hypertension Drugs Industry Drivers and Opportunities
- 6.31 Rest of Asia Pacific Market Size Outlook and Revenue Growth Forecasts
- 6.32 Rest of Asia Pacific Pulmonary Arterial Hypertension Drugs Industry Drivers and Opportunities
- 6.33 Brazil Market Size Outlook and Revenue Growth Forecasts
- 6.34 Brazil Pulmonary Arterial Hypertension Drugs Industry Drivers and Opportunities
- 6.36 Argentina Market Size Outlook and Revenue Growth Forecasts
- 6.36 Argentina Pulmonary Arterial Hypertension Drugs Industry Drivers and Opportunities
- 6.37 Rest of South America Market Size Outlook and Revenue Growth Forecasts
- 6.38 Rest of South America Pulmonary Arterial Hypertension Drugs Industry Drivers and Opportunities
- 6.39 Middle East Market Size Outlook and Revenue Growth Forecasts
- 6.40 Middle East Pulmonary Arterial Hypertension Drugs Industry Drivers and Opportunities
- 6.41 Africa Market Size Outlook and Revenue Growth Forecasts
- 6.42 Africa Pulmonary Arterial Hypertension Drugs Industry Drivers and Opportunities

## **7. PULMONARY ARTERIAL HYPERTENSION DRUGS MARKET OUTLOOK**

## **ACROSS SCENARIOS**

- 7.1 Low Growth Case
- 7.2 Reference Growth Case
- 7.3 High Growth Case

## **8. PULMONARY ARTERIAL HYPERTENSION DRUGS COMPANY PROFILES**

- 8.1 Profiles of Leading Pulmonary Arterial Hypertension Drugs Companies in the Market
- 8.2 Business Descriptions, SWOT Analysis, and Growth Strategies
- 8.3 Financial Performance and Key Metrics
- Asklepion Pharmaceuticals LLC
- AstraZeneca Plc
- Bayer AG
- Daiichi Sankyo Co. Ltd
- Dr Reddys Laboratories Ltd
- Eiger BioPharmaceuticals Inc
- Gilead Sciences Inc
- GlaxoSmithKline Plc
- Johnson and Johnson Services Inc
- Lupin Ltd
- Merck and Co. Inc
- Novartis AG
- Pfizer Inc
- Teva Pharmaceutical Industries Ltd
- United Therapeutics Corp

## **9. APPENDIX**

- 9.1 Scope of the Report
- 9.2 Research Methodology and Data Sources
- 9.3 Glossary of Terms
- 9.4 Market Definitions
- 9.5 Contact Information

## I would like to order

Product name: Pulmonary Arterial Hypertension Drugs Market Size, Trends, Analysis, and Outlook By Mechanism of Action (Prostacyclin Analogs, Endothelin Receptor Antagonists (ERAs), Phosphodiesterase (PDE) Inhibitors, Soluble Guanylate Cyclase Stimulators (SGCSs)), By Route of Administration ( Oral, Injectable, Inhalation), by Region, Country, Segment, and Companies, 2024-2030

Product link: <https://marketpublishers.com/r/P60D2CB290E4EN.html>

Price: US\$ 3,980.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P60D2CB290E4EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below  
and fax the completed form to +44 20 7900 3970